Evaluation of the Safety, Efficacy, Dose Response of the Bimatoprost Drug Ring System (BIM-DRS) in Pseudophakic Patients Diagnosed With Open Angle Glaucoma or Ocular Hypertension
← catalyst calendarNCT07641296 · readout in 193 d
Sponsored by SpyGlass Pharma, Inc. (industry) · SGP — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Non randomized · Single · Treatment
Enrollment
24estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-31 | estimated | When the study began enrolling |
| Primary completion | 2027-02-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-03-31 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Glaucoma
- Ocular Hypertension
Interventions
- Drug: BIM-DRS Low Dose
- Drug: BIM-DRS High Dose
- Device: SpyGlass IOL with silicone pads (no drug)
Primary outcome
what the primary-completion date above is the date OFMean IOP change from Baseline (mmHg)
measured Postoperative Week 2, Week 6, and Month 3.
Permalink · SGP's whole pipeline · Catalyst calendar · Every registered study · What changed